|
|
|
|
| LEADER |
02934nmm a2200277 u 4500 |
| 001 |
EB001085495 |
| 003 |
EBX01000000000000000844859 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
151215 ||| eng |
| 020 |
|
|
|a 9784431557142
|
| 100 |
1 |
|
|a Kizaki, Masahiro
|e [editor]
|
| 245 |
0 |
0 |
|a Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia
|h Elektronische Ressource
|c edited by Masahiro Kizaki
|
| 250 |
|
|
|a 1st ed. 2016
|
| 260 |
|
|
|a Tokyo
|b Springer Japan
|c 2016, 2016
|
| 300 |
|
|
|a VIII, 193 p. 26 illus., 20 illus. in color
|b online resource
|
| 505 |
0 |
|
|a 1. Identification and Biology of CML Stem Cells.- 2. Molecular Mechanisms of CML Stem Cell Maintenance -- 3. Roles for Signaling Molecules in the Growth and Survival of CML Cells.- 4. Goal of CML Treatment in the Tyrosine Kinase Inhibitor Era.- 5. Biomarkers for Determining the Prognosis of CML -- 6. Updated European Leukemia Net Recommendations for the Management of CML -- 7. Optimal Monitoring of CML Treatment: Molecular and Mutation Analysis -- 8. Recommendations for Management of CML in the Era of Second-Generation TKIs -- 9. Role of New TKIs and Combinations with Interferon-α for the Treatment of CML -- 10. Safety Profiles of First-Line TKIs and Managing Adverse Effects -- 11. Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance -- 12. Discontinuation of Therapy and Treatment-Free Remission in CML.
|
| 653 |
|
|
|a Hematology
|
| 653 |
|
|
|a Hematology
|
| 653 |
|
|
|a Oncology
|
| 653 |
|
|
|a Oncology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-4-431-55714-2?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.15
|
| 520 |
|
|
|a Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML. Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.
|